 |
The Journal of the Japanese Society for Clinical Microbiology |
Biblioraphy Information
| ArticleTitle |
Evaluation of the association of quinolone prescriptions and duration of administration with the rate of levofloxacin resistance of Escherichia coli in urine |
| Language |
J |
| AuthorList |
Masaru Samura1), Toshihiro Yanagida2), Naoki Hirose1), Takenori Kurata1), Junichi Ishii1), Fumio Nagumo1), Sakura Koshioka1), Masaki Uchida1), Shunya Yamamoto1), Junki Inoue1), Hisakazu Sekine1), Norifumi Kunika3), Hiroyuki Kunishima4) |
| Affiliation |
1) Department of Pharmacy, Yokohama General Hospital
2) Department of Clinical Laboratory, Yokohama General Hospital
3) Department of Internal Medicine, Yokohama General Hospital
4) Department of Infectious Diseases, St.Marianna University School of Medicine Hospital |
| Publication |
J.J.C.M.: 27 (3), 149-157, 2017 |
| Received |
December 8, 2016 |
| Accepted |
February 21, 2017 |
| Abstract |
Recently, the rate of levofloxacin (LVFX) resistance of Escherichia coli (E. coli) has increased. Therefore, it is important to study the rate of LVFX resistance of E. coli and to evaluate potential risk factors and predispositions for resistance at our hospital. Although there is a general association between resistant bacteria and antimicrobial use in general, reports evaluating this association for outpatient use of quinolones are few. In this study, we examined the correlation of quinolones use, measured by antimicrobial use density (AUD), and days of therapy (DOT) with the rate of LVFX resistance of E. coli in urine samples collected at our hospital. There was no significant correlation of quinolones AUD or DOT with the rate of LVFX resistance of E. coli collected every three months between April 1, 2008 and March 31, 2016 (R=0.21, p=0.27; R=-0.08, p=0.78, respectively). However, we found a significant correlation between the rate of extended-spectrum β-lactamase (ESBL)-producing E. coli and the rate of LVFX resistance in urine samples collected every three months between April 1, 2012 and March 31, 2016 (R=0.64, p<0.01). Our results suggest that the rate of ESBL-producing E. coli in the urine, rather than the quinolones AUD and DOT, is a risk factor for LVFX resistance at our hospital. |
| Keywords |
ESBL |
|
